NOV 29, 2015 10:30 AM PST

New Molecule Shrinks Melanoma Tumors and Prevents Relapse

WRITTEN BY: Xuan Pham
Researchers at Sanford Burnham Prebys Medical Discovery Institute announced the discovery of a new anti-cancer compound, named SBI-756, that can halt the growth of melanoma tumors.
 
Melanoma is a deadly form of skin cancer caused by ultraviolet radiation damages to the skin cells. According to the Skin Cancer Foundation, melanoma kills an estimated 9,940 Americans each year.
 
Melanoma is the deadliest form of skin cancer.

While melanoma can be curable if treated early, some forms of melanomas can adapt and quickly become resistant to today’s leading cancer regimens. In about 50% of patients, melanomas are caused by mutations in the BRAF gene, which makes proteins for cell growth. Currently, the Food and Drug Administration has approved one anti-cancer drug, Vemurafenib, for BRAF-induced melanomas. However, despite early tumor shrinkage, some patients inevitably relapse as the tumor cells become resistant to Vemurafenib. For these patients, there hasn’t been another alternative.
 
The newly discovered compound, SBI-756, has a different target than the conventional Vemurafenib. Instead of inhibiting the BRAF gene, SBI-756 targets cell growth at the start of translation. Specifically, SBI-756 targets the eukaryotic initiation factor 4G1 (also known as eIF4G1) in the translation initiation complex. Every cell depends on the translation machinery to convert mRNA messages into protein products. So, in effect, SBI-756 stops cell growth at its roots, making it a first-in-class drug. 
 
"The unique target of SBI-756 makes it especially promising for use in combination therapy," said Ze'ev Ronai, senior author of the study. "A major issue limiting the effectiveness of current melanoma therapies is that tumors become resistant to treatment. Combining drugs that come at a melanoma from different angles may help overcome the problem of drug resistance."
 
Indeed, SBI-756 slowed the growth of BRAF mutant melanomas in cells. In mice, the drug delayed onset and decreased the number of melanoma tumors. When the researchers co-administered SBI-756 with Vemurafenib, they reported that tumors shrank and did not reoccur. Taken together, the data suggests that SBI-756 has great potential to treat resistant and unresponsive BRAF-induced tumors.
 
"The ability of this compound to delay or eliminate the formation of resistant melanomas is very exciting," said Ronai.
 
 The team also reported that efficacy of the compound could be attained with relatively low doses. Furthermore, even when the compound was given to mice over a long amount of time, the team did not find any evidence of toxicity.
 
The SBI-756 was the product of over seven years of research. But Ronai and his team still have additional tweaking to do before the compound is ready for human clinical trials. And because SBI-756 targets the translation machinery, a fundamental component for cell growth, the team is looking to apply the compound to other tumors. 
 
"We hope that we're going to come up with the next generation of the compound that can go into clinical trials--first in melanoma but likely in other tumors," Ronai said.
 
Watch the video to learn the warning signs of melanomas. 
 

Sources: Cancer Research, EurekAlert
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 16, 2019
Health & Medicine
OCT 16, 2019
Pregnancy Related Deaths Are Largely Preventable
A new report from the Centers for Disease Control (CDC) highlights just how poor maternal health is in the United States. Although data is limited, the dat...
OCT 16, 2019
Clinical & Molecular DX
OCT 16, 2019
Say Good Morning To Your Friendly Health-Bot
Sending young children to school can be scary for parents. Children are likely to be exposed to a massive amount of germs every day. Though parents do thei...
OCT 16, 2019
Health & Medicine
OCT 16, 2019
Low Number of Vaccine Injury Claims Demonstrate Their Safety
To spread awareness of vaccine safety, New York Times reporters Pam Belluck and Reed Abelson wrote a comprehensive report about vaccine injury claim data....
OCT 16, 2019
Cardiology
OCT 16, 2019
Opioid Addiction Comes With Increased Risk Of Infection
Public health officials have put decades of work into the battle against infectious diseases. Now, this progress is at risk of being dismantled. A recent s...
OCT 16, 2019
Microbiology
OCT 16, 2019
Fibromyalgia Linked to Gut Microbes
Using clinical samples, scientists identified differences in the microbial population in the guts of people with fibromyalgia....
OCT 16, 2019
Clinical & Molecular DX
OCT 16, 2019
A Blood Drop Test for Rapid Detection of Traumatic Brain Injury
A study published by Yue et al., in August 2019, reported that a simple blood test (a few drops of blood) can detect traumatic brain injury efficiently and...
Loading Comments...